23.45
+0.02(+0.09%)
Currency In USD
| Previous Close | 23.43 |
| Open | 23.43 |
| Day High | 23.45 |
| Day Low | 23.41 |
| 52-Week High | 23.46 |
| 52-Week Low | 8.61 |
| Volume | 88,882 |
| Average Volume | 292,217 |
| Market Cap | 151.54M |
| PE | -4.23 |
| EPS | -5.55 |
| Moving Average 50 Days | 20.23 |
| Moving Average 200 Days | 13.93 |
| Change | 0.02 |
Assertio Announces Leadership Transition
GlobeNewswire Inc.
Oct 28, 2025 1:15 PM GMT
Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oc
Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV
GlobeNewswire Inc.
Sep 15, 2025 1:00 PM GMT
New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsyStudy addresses lack of awareness and real-world data with oral film formulation of clo
Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association
GlobeNewswire Inc.
Sep 10, 2025 11:30 AM GMT
Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or olderAbstract is now availabl